The purpose of this study is to explore the effect of indinavir on the clotting system and to collect information about bleeding patterns and coagulation factor usage in HIV-1 infected hemophiliacs who have not received a protease inhibitor previously and who will receive combined therapy of indinavir and two nucleoside reverse transcriptase inhibitors. Based on reports from physicians treating HIV-1 infected hemophiliacs, there is concern that hemophiliac patients receving combination antiretroviral regimens containing HIV protease inhibitors, including those containing indinavir, have an increased incidence of spontaneous bleeding episodes.
Showing the most recent 10 out of 782 publications